Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/207533
Title: | Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma |
Author: | Rosiñol, Laura Oriol, Albert Rios, Rafael Blanchard, Maria Jesús Jarque, Isidro Bargay, Juan Hernández, Miguel Teodoro Cabanas, Valentín Carrillo Cruz, Estrella Sureda, Anna Martínez López, Joaquín Krsnik, Isabel González, María Esther Casado, Luís Felipe Martí, Josep Maria Encinas, Cristina Arriba, Felipe de Palomera, Luis Sampol, Antonia Gonzalez Montes, Yolanda Cabezudo, Elena Paiva, Bruno Puig, Noemí Cedena, Maria Teresa Cruz, Javier de la Mateos, María Victoria San Miguel, Jesús Lahuerta, Juan José Bladé, J. (Joan) |
Keywords: | Mieloma múltiple Quimioteràpia Multiple myeloma Chemotherapy |
Issue Date: | 2-Nov-2023 |
Publisher: | American Society of Hematology |
Abstract: | From November 2014 to May 2017, 332 patients homogeneously treated with bortezomib, lenalidomide, and dexamethasone (VRD) induction, autologous stem cell transplant, and VRD consolidation were randomly assigned to receive maintenance therapy with lenalidomide and dexamethasone (RD; 161 patients) vs RD plus ixazomib (IRD; 171 patients). RD consisted of lenalidomide 15 mg/d from days 1 to 21 plus dexamethasone 20 mg/d on days 1 to 4 and 9 to 12 at 4-week intervals, whereas in the IRD arm, oral ixazomib at a dose of 4 mg on days 1, 8, and 15 was added. Therapy for patients with negative measurable residual disease (MRD) after 24 cycles was discontinued, whereas those who tested positive for MRD remained on maintenance with RD for 36 more cycles. After a median follow-up of 69 months from the initiation of maintenance, the progression-free survival (PFS) was similar in both arms, with a 6-year PFS rate of 61.3% and 55.6% for RD and IRD, respectively (hazard ratio, 1.136; 95% confidence interval, 0.809-1.603). After 2 years of maintenance, treatment was discontinued in 163 patients with negative MRD, whereas 63 patients with positive MRD continued with RD therapy. Maintenance discontinuation in patients tested negative for MRD resulted in a low progression rate (17.2% at 4 years), even in patients with high-risk features. In summary, our results show the efficacy of RD maintenance and support the safety of maintenance therapy discontinuation in patients with negative MRD at 2 years. This trial was registered at www.clinicaltrials.gov as #NCT02406144 and at EudraCT as 2014-00055410. |
Note: | Reproducció del document publicat a: https://doi.org/10.1182/blood.2022019531 |
It is part of: | Blood, 2023, vol. 142, num. 18, p. 1518-1528 |
URI: | http://hdl.handle.net/2445/207533 |
Related resource: | https://doi.org/10.1182/blood.2022019531 |
ISSN: | 1528-0020 |
Appears in Collections: | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
GEM14-v4.pdf | 297.03 kB | Adobe PDF | View/Open Request a copy |
Document embargat fins el 28-7-2024
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.